Table 2.

Adverse effects

	SC group (n = 8)	IV Group (n = 8)	Placebo (n = 7)	P-value*
Self-reported AE incidence
	6 (75.0)	6 (75.0)	7 (100)	0.78
Nausea
Mild	2 (25.0)	1 (12.5)	0 (0)
Moderate	0 (0)	3 (37.5)	2 (28.6)	0.53
Severe	0 (0)	0 (0)	0 (0)
Vomiting
Mild	2 (25.0)	0 (0)	0 (0)
Moderate	1 (12.5)	1 (12.5)	1 (14.3)	0.41
Severe	0 (0)	0 (0)	0 (0)
Shivering
Mild	1 (12.5)	0 (0)	6 (85.7)
Moderate	1 (12.5)	0 (0)	0 (0)	0.01**
Severe	0 (0)	0 (0)	0 (0)
Sedation
Mild	1 (12.5)	2 (25.0)	1 (14.3)
Moderate	0 (0)	1 (12.5)	2 (28.6)	0.38
Severe	0 (0)	0 (0)	0 (0)
Blurred vision
Mild	1 (12.5)	3 (37.5)	1 (14.3)
Moderate	0 (0)	0 (0)	0 (0)	0.41
Severe	0 (0)	0 (0)	0 (0)
Diplopia
Mild	0 (0)	1 (12.5)	1 (14.3)
Moderate	0 (0)	0 (0)	0 (0)	0.99**
Severe	0 (0)	0 (0)	0 (0)
Dizziness
Mild	1 (12.5)	3 (37.5)	1 (14.3)
Moderate	0 (0)	0 (0)	0 (0)	0.41
Severe	0 (0)	0 (0)	0 (0)
Anxiety
Mild	0 (0)	1 (12.5)	2 (28.6)
Moderate	0 (0)	0 (0)	1 (14.3)	0.23**
Severe	0 (0)	0 (0)	0 (0)
Pruritus
Mild	4 (50.0)	0 (0)	1 (14.3)
Moderate	0 (0)	2 (25.0)	1 (14.3)	0.53
Severe	0 (0)	0 (0)	0 (0)
Euphoria, Amnesia, Hallucinations, Nystagmus
	0 (0)	0 (0)	0 (0)
Hemodynamic Adverse Effects
Hemodynamic AE incidence
	3 (37.5)	3 (37.5)	2 (28.6)	0.92
Systolic Blood pressure
< 80 mmHg	2 (25.0)	1 (12.5)	1 (14.3)	0.78
> 170 mmHg	0 (0)	1 (12.5)	1 (14.3)	0.68
Heart Rate
< 40 bpm	0 (0)	2 (25.0)	0 (0)	0.70
> 120 bpm	1 (12.5)	1 (12.5)	0 (0)	0.99

Incidences are presented as n (%)

SC subcutaneous, IV intravenous, AE adverse effects

^*Chi-squared test

^**Chi-squared test, with Yates’ correction